Co-Diagnostics (CODX) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
November 10, 2022 4:13 PM ESTNearing commencement of clinical evaluations for the Co-Dx PCR Home platformCOVID-19 test volumes continue to impact third quarter results
SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022.
Third Quarter 2022 Financial Results:
Revenue of $5.1 million, down from $30.1 million during the prior year period, but an... More